Leif Bertilsson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. doi request reprint CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking
    Margareta Ramsjö
    Division of Clinical Pharmacology, Department of Laboratory Medicine at Karolinska Institutet, Karolinska University Hospital Huddinge C1 68, 14186 Stockholm, Sweden
    Eur J Clin Pharmacol 66:871-7. 2010
  2. pmc Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
    Leif Bertilsson
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    Br J Clin Pharmacol 53:111-22. 2002
  3. ncbi request reprint Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
    Roza Ghotbi
    Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, C1 68, 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 63:537-46. 2007
  4. ncbi request reprint Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans
    Natasa Djordjevic
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Drug Metab Pharmacokinet 28:93-7. 2013
  5. doi request reprint Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation
    Hadi Molanaei
    Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 68:571-7. 2012
  6. doi request reprint Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1175-9. 2008
  7. doi request reprint Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes
    Fazleen H M Hatta
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet Karolinska University Hospital, Huddinge 141 86 Stockholm, Sweden
    Eur J Clin Pharmacol 68:1033-42. 2012
  8. ncbi request reprint Xanthine oxidase activity is influenced by environmental factors in Ethiopians
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Eur J Clin Pharmacol 59:533-6. 2003
  9. ncbi request reprint Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans
    Natasa Djordjevic
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Clin Pharmacol 52:1527-34. 2012
  10. doi request reprint Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
    Roza Ghotbi
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 9:208-17. 2009

Collaborators

Detail Information

Publications47

  1. doi request reprint CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking
    Margareta Ramsjö
    Division of Clinical Pharmacology, Department of Laboratory Medicine at Karolinska Institutet, Karolinska University Hospital Huddinge C1 68, 14186 Stockholm, Sweden
    Eur J Clin Pharmacol 66:871-7. 2010
    ..To compare CYP2C19 enzyme activity between Swedes and Koreans controlling for the effect of CYP2C19 genotype, sex, oral contraceptive use, and smoking habits...
  2. pmc Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
    Leif Bertilsson
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    Br J Clin Pharmacol 53:111-22. 2002
    ..The present-day knowledge on the influence of the genetic variability in CYP2D6 on the clinical pharmacokinetics and therapeutic effects/adverse effects of psychotropic drugs is reviewed...
  3. ncbi request reprint Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
    Roza Ghotbi
    Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, C1 68, 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 63:537-46. 2007
    ..To investigate the CYP1A2 genotype-phenotype relationship and to compare CYP1A2 genetic polymorphisms and enzyme activity in terms of the effect of smoking and oral contraceptive (OC) use in Swedes and Koreans...
  4. ncbi request reprint Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans
    Natasa Djordjevic
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Drug Metab Pharmacokinet 28:93-7. 2013
    ..0001), even among carriers of rapid genotypes. We report major differences in CYP2A6 enzyme activity between Swedes and Koreans mainly due to CYP2A6 genetic variation but not exclusively...
  5. doi request reprint Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation
    Hadi Molanaei
    Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 68:571-7. 2012
    ....
  6. doi request reprint Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1175-9. 2008
    ..The aim of this study was to compare the impact of the CYP2C19*17 allele on omeprazole single-dose kinetics with escitalopram exposure at steady state in volunteers genotyped as either CYP2C19*17/*17 or CYP2C19*1/*1...
  7. doi request reprint Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes
    Fazleen H M Hatta
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet Karolinska University Hospital, Huddinge 141 86 Stockholm, Sweden
    Eur J Clin Pharmacol 68:1033-42. 2012
    ..To search for a relationship between ultra-rapid metabolism catalysed by cytochrome P450 2C9 (CYP2C9) and its genotypes...
  8. ncbi request reprint Xanthine oxidase activity is influenced by environmental factors in Ethiopians
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Eur J Clin Pharmacol 59:533-6. 2003
    ..To investigate xanthine oxidase (XO) polymorphism in Ethiopians and influence of environmental factors, smoking habit and gender-related differences on enzyme activity among Ethiopians living in Ethiopia or Sweden...
  9. ncbi request reprint Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans
    Natasa Djordjevic
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Clin Pharmacol 52:1527-34. 2012
    ..In conclusion, Koreans display higher NAT2 activity than Swedes regardless of NAT2 genotype. Ethnicity, OC use, and genotype determine NAT2 activity, whereas sex is the only determinant of XO activity...
  10. doi request reprint Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
    Roza Ghotbi
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 9:208-17. 2009
    ..In conclusion, the CYP1A2 gene expression is influenced by the extent of DNA methylation and displays ASE, mechanisms contributing to the large interindividual differences in CYP1A2 gene expression...
  11. pmc Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers
    R Michael Baldwin
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Br J Clin Pharmacol 65:767-74. 2008
    ..The CYP2C19*17 allele had been associated with a two- and fourfold decrease in omeprazole and S/R-mephenytoin metabolic ratios...
  12. ncbi request reprint Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes
    Hyung Keun Roh
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Basic Clin Pharmacol Toxicol 95:112-9. 2004
    ..In these patients omeprazole accumulated from the first to the eighth dose similar to that in the heterozygotes...
  13. doi request reprint Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease
    Hadi Molanaei
    Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 66:269-73. 2010
    ..We studied the influence of three factors on drug disposition: genetic polymorphism, impaired renal excretion of drug metabolites, and the possible elimination by hemodialysis (HD), using codeine as a model drug...
  14. ncbi request reprint The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
    Magnus Christensen
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Clin Pharmacol Ther 73:517-28. 2003
    ....
  15. ncbi request reprint Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenetics 12:375-83. 2002
    ..Additional factors remain to be elucidated to fully explain the interethnic differences in CYP2D6 activity...
  16. ncbi request reprint Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
    Eleni Aklillu
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Mol Pharmacol 64:659-69. 2003
    ....
  17. doi request reprint Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin
    Linda Björkhem-Bergman
    Division of Clinical Pharmacology C1 68, Karolinska University Hospital, Huddinge, Karolinska Institutet, SE 141 86, Stockholm, Sweden
    Drug Metab Dispos 41:1488-93. 2013
    ..In conclusion, the 4β-hydroxycholesterol ratio is comparable to midazolam clearance as a marker of CYP3A4 induction, and each may be used to evaluate CYP3A4 induction in clinical trials evaluating drug-drug interactions for new drugs. ..
  18. ncbi request reprint Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
    Natasa Djordjevic
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, C1 68, SE 14186, Stockholm, Sweden
    Eur J Clin Pharmacol 64:381-5. 2008
    ..To investigate the influence of coffee consumption on CYP1A2 enzyme activity controlling for the effects of smoking and oral contraceptive (OC) use among Serbs and Swedes and to compare CYP1A2 activity between the two populations...
  19. ncbi request reprint Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
    Cristina Rodriguez-Antona
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Biochem Biophys Res Commun 338:299-305. 2005
    ..The data indicate the existence of a genetic CYP3A4 polymorphism with functional importance for interindividual differences in enzyme expression...
  20. pmc Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity
    Karin Hellman
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Neurotec, Karolinska Institutet at Huddinge University Hospital, S 141 86 Huddinge, Sweden
    Br J Clin Pharmacol 56:337-40. 2003
    ..To determine CYP2C19 and CYP2D6 activity in patients with multiple sclerosis (MS) before and during interferon (IFN)-beta treatment...
  21. ncbi request reprint Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man
    Rajaa A Mirghani
    Division of Clinical Pharmacology, Department of Medical Laboratory Sciences and Technology, Karolinska Institutet and Hospital Pharmacy, C1 68 Huddinge University Hospital, 141 86 Stockholm, Sweden
    Eur J Clin Pharmacol 59:23-8. 2003
    ..To investigate the usefulness of the 3-hydroxylation of quinine as a biomarker reaction for the activity of CYP3A4 in man and to study the interindividual variation in the metabolic ratio (MR), i.e. quinine/3-hydroxyquinine...
  22. doi request reprint Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients
    Roza Ghotbi
    Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge Karolinska Institutet, 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 66:465-74. 2010
    ....
  23. ncbi request reprint High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of CYP2A6 Variant Alleles in Ethiopian Population
    Eleni Aklillu
    1 Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    OMICS 18:446-53. 2014
    ....
  24. ncbi request reprint Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers
    Annika Allqvist
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Eur J Clin Pharmacol 63:173-9. 2007
    ..Most of them, however, involved the KTZ racemate. KTZ racemate and the separate enantiomers, 2R,4R; 2R,4S; 2S,4S, and 2S,4R, were evaluated for their selectivity in inhibiting alprazolam and quinine metabolism...
  25. ncbi request reprint Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression
    Ikuko Kishida
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, C 168, SE 141 86 Stockholm, Sweden
    Neuropsychopharmacology 32:2143-51. 2007
    ..002) and L/S subjects (p=0.002). There was no effect of 5-HTTVNTR. Our findings show that the 5-HTTLPR polymorphism affects 5-HIAA and HVA concentrations among treatment-resistant patients with mood disorders...
  26. pmc Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations
    Eliford Ngaimisi
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 8:e67946. 2013
    ..We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations...
  27. doi request reprint Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9
    Anders Helldén
    Department of Laboratory Medicine, Karolinska Institutet, Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
    Eur J Clin Pharmacol 66:791-5. 2010
    ..The enzyme is polymorphic, and all known alleles, for example, CYP2C9*2 and*3, give decreased activity. Ultra-high activity of the enzyme has not yet been reported...
  28. pmc 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
    Ulf Diczfalusy
    Department of Laboratory Medicine, Division of Clinical Chemistry, Karolinska Institutet, Stockholm, Sweden
    Br J Clin Pharmacol 71:183-9. 2011
    ..The use of an endogenous CYP3A marker has obvious advantages and may be of value both during drug development and for monitoring CYP3A activity in patients...
  29. ncbi request reprint Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study
    Chiaki Kawanishi
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, 14186 Stockholm, Sweden
    Eur J Clin Pharmacol 59:803-7. 2004
    ..We investigated the relationship between persistent mood disorders and the duplication of the CYP2D6 gene, which encodes an enzyme with increased activity...
  30. pmc Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
    Karin Herrlin
    Division of Clinical Pharmacology at Department of Medicine Laboratory, Karolinska Institutet at Huddinge University Hospital, Huddinge, Sweden
    Br J Clin Pharmacol 56:415-21. 2003
    ..To investigate pharmacokinetics of the enantiomers of citalopram (CT) and its metabolites desmethylcitalopram (DCT) and didesmethylcitalopram (DDCT) in Swedish healthy volunteers in relation to CYP2C19 and CYP2D6 geno- and phenotypes...
  31. ncbi request reprint Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
    Buster Mannheimer
    Karolinska Institutet, Department of Clinical Science and Education at Södersjukhuset, Stockholm, Sweden
    Eur J Clin Pharmacol 70:695-9. 2014
    ..The purpose of the present study was to investigate the predictive value of the risperidone metabolic ratio for the individual CYP2D6 genotype...
  32. ncbi request reprint Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
    Magnus Christensen
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Clin Pharmacol Ther 71:141-52. 2002
    ....
  33. ncbi request reprint The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity
    Agneta Wennerholm
    Division of Clinical Pharmacology, Department of Medical Laboratory Sciences and Technology, Karolinska Institutet at Huddinge University Hospital, Stockholm
    Clin Pharmacol Ther 71:77-88. 2002
    ....
  34. ncbi request reprint Metabolism and elimination of quinine in healthy volunteers
    Rajaa A Mirghani
    Department of Laboratory Medicine and Technology, C1 68 Huddinge University Hospital, 141 86 Stockholm, Sweden
    Eur J Clin Pharmacol 59:423-7. 2003
    ....
  35. pmc Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity
    Sebastian Hartter
    Department of Psychiatry and Institute of Occupational, Social and Environmental Medicine University of Mainz, Mainz, Germany
    Br J Clin Pharmacol 56:679-82. 2003
    ..The aim of this study was to assess the influence of concomitant caffeine intake on the pharmacokinetics of oral melatonin, a probe drug for CYP1A2 activity...
  36. ncbi request reprint A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    Clin Pharmacol Ther 79:103-13. 2006
    ..A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background...
  37. ncbi request reprint Dose of proton pump inhibitors and the CYP2C19 genotype
    Leif Bertilsson
    Basic Clin Pharmacol Toxicol 95:1. 2004
  38. ncbi request reprint Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)
    Ksenia Goryachkina
    Course of Clinical Pharmacology, Department of Hospital Therapy, St Petersburg I I Mechnikov State Medical Academy, Piskarevsky Prospect, 47, 195 067 St Petersburg, Russia
    Eur J Clin Pharmacol 64:275-82. 2008
    ..To investigate the influence of paroxetine on metoprolol concentrations and its effect in patients treated for acute myocardial infarction (AMI) who are routinely given paroxetine as a co-treatment of depression...
  39. ncbi request reprint Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo
    Agneta Wennerholm
    Division of Clinical Pharmacology C1 68, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 62:539-46. 2006
    ..To study the extent of in vivo inhibition by the antimalarial drug amodiaquine, its active metabolite N-desethylamodiaquine, or both, of the metabolism of four probe drugs of the enzymes CYP2D6, CYP2C19, CYP2C9 and CYP1A2...
  40. ncbi request reprint Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 16:565-8. 2006
    ..However, the present study had sufficient power to detect only a considerably smaller rifampicin-induced increase in 4beta-hydroxycholesterol in carriers of the SLCO1B1 c.521C allele compared to subjects with the reference genotype...
  41. ncbi request reprint CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
    Rajaa A Mirghani
    Department of Clinical Toxicology, Central Laboratories and Blood Bank, King Fahad Medical City, Riyadh 11525, Kingdom of Saudi Arabia
    Pharmacogenet Genomics 16:637-45. 2006
    ..To study the correlation between CYP3A5 genotype and quinine 3-hydroxylation in black Tanzanian and Swedish Caucasians as well as to investigate the interethnic differences in CYP3A activity between the two populations...
  42. ncbi request reprint CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited
    Vural Ozdemir
    Biomarker and Clinical Pharmacology Unit, VA Long Beach Medical Center, and School of Medicine, University of California Irvine, 3844 East 15th Street, Long Beach, Irvine, CA 90804, USA
    Pharmacogenet Genomics 17:339-47. 2007
    ..We prospectively evaluated significance of CYP2D6 genetic variation for prolactin response to perphenazine (a model first-generation antipsychotic) in Asians...
  43. ncbi request reprint Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, FIN 20520 Turku, Finland
    Fundam Clin Pharmacol 21:379-86. 2007
    ..The higher than expected frequency of the CYP3A5*1*1 genotype and the CYP2C8*3*3/CYP2C9*2*2 haplotype may influence the response to treatment with drugs metabolized by these enzymes...
  44. doi request reprint 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
    Ulf Diczfalusy
    Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden
    Pharmacogenet Genomics 18:201-8. 2008
    ..To study the potential endogenous marker of CYP3A activity, 4beta-hydroxycholesterol, and its relation to sex and the CYP3A5 geno/haplotypes and compare with CYP3A4/5 catalyzed 3-hydroxylation of quinine in the three major races...
  45. ncbi request reprint Voriconazole and fluconazole increase the exposure to oral diazepam
    Teijo I Saari
    Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku, P O Box 52, Kiinamyllynkatu 4 8, 20520, Turku, Finland
    Eur J Clin Pharmacol 63:941-9. 2007
    ..We assessed the effect of voriconazole and fluconazole on the pharmacokinetics and pharmacodynamics of diazepam...
  46. ncbi request reprint Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy
    Kari Laine
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland
    Ther Drug Monit 26:685-7. 2004
    ....
  47. ncbi request reprint Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects
    Agneta Wennerholm
    Division of Clinical Pharmacology C1 68, Karolinska University Hospital, Huddinge, 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 61:113-8. 2005
    ..1) To determine the pharmacokinetic parameters of alprazolam and its two metabolites in plasma from healthy volunteers; (2) to identify a suitable single time point to take a plasma sample for CYP3A phenotyping...